Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | PYGB | P11216 | 7/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | CD69 | Q07108 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9302995 | 0.87 | CA1 (0.60) | ALDH1A1THRBMAPK1PYGBGAA | |
| SCHEMBL9302990 | 0.87 | CA1 (0.60) | ALDH1A1THRBMAPK1PYGBGAA | |
| SCHEMBL24645911 | 0.86 | MAPK1 (0.57) | ALDH1A1THRBMAPK1PYGBGAA | |
| SCHEMBL14081291 | 0.84 | ALDH1A1 (0.53) | ALDH1A1THRBMAPK1PYGBGAA | |
| SCHEMBL25511170 | 0.84 | ALDH1A1 (0.53) | ALDH1A1THRBMAPK1PYGBGAA | |
| SCHEMBL16217717 | 0.84 | ALDH1A1 (0.53) | ALDH1A1THRBMAPK1PYGBGAA | |
| SCHEMBL10787019 | 0.84 | MAPK1 (0.61) | ALDH1A1THRBMAPK1PYGBGAA | |
| SCHEMBL10625975 | 0.84 | MAPK1 (0.61) | ALDH1A1THRBMAPK1PYGBGAA | |
| SCHEMBL23136470 | 0.84 | MAPK1 (0.61) | ALDH1A1THRBMAPK1PYGBGAA | |
| SCHEMBL10529893 | 0.84 | MAPK1 (0.61) | ALDH1A1THRBMAPK1PYGBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210395734-A1 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2021-12-23 | — | — | US | disclosed |
| US-10875884-B2 | Compositions and methods for modulating angiopoietin-like 3 expression | ISIS PHARMACEUTICALS, INC. (US) | 2020-12-29 | — | — | US | disclosed |
| US-10844379-B2 | Conjugated antisense compounds and their use | IONIS PHARMACEUTICALS, INC. (US) | 2020-11-24 | — | — | US | disclosed |
| US-20200224198-A1 | COMPOSITIONS AND METHODS FOR MODULATING HBV EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2020-07-16 | — | — | US | disclosed |
| US-20190016748-A1 | COMPOSITIONS AND METHODS FOR MODULATING ANGIOPOIETIN-LIKE 3 EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2019-01-17 | — | — | US | disclosed |
| US-9957504-B2 | Compositions and methods for modulating apolipoprotein (a) expression | IONIS PHARMACEUTICALS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| WO-2015168635-A2 | COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2015-11-05 | — | — | WO | disclosed |
| WO-2015168532-A2 | COMPOSITIONS AND METHODS FOR MODULATING PKK EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2015-11-05 | — | — | WO | disclosed |
| WO-2014179620-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | ISIS PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | WO | disclosed |
| WO-2014179627-A2 | COMPOSITIONS AND METHODS FOR MODULATING HBV AND TTR EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10875884-B2 | Compositions and methods for modulating angiopoietin-like 3 expression | TEK, PLIN3, FABP3 | ALDH1A1 2808/4885THRB 2520/4885MAPK1 3617/4885 |
| US-20200224198-A1 | COMPOSITIONS AND METHODS FOR MODULATING HBV EXPRESSION | HAVCR2, HCCS, HDGF | ALDH1A1 3686/4885THRB 1298/4885MAPK1 4339/4885 |
| US-20190016748-A1 | COMPOSITIONS AND METHODS FOR MODULATING ANGIOPOIETIN-LIKE 3 EXPRESSION | TEK, PLIN3, FABP3 | ALDH1A1 2808/4885THRB 2520/4885MAPK1 3617/4885 |
| US-20210395734-A1 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION | APOB, APOL1, LDLR | ALDH1A1 2605/4885THRB 2086/4885MAPK1 4093/4885 |
| US-10844379-B2 | Conjugated antisense compounds and their use | CSGALNACT1, GALNT1, GALNT6 | ALDH1A1 1877/4885THRB 1074/4885MAPK1 3983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.